Armin Garmany

Armin Garmany

Auto-generated profile, based on publicly available information

Armin Garmany

Mayo Clinic Alix School of Medicine, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN (A.G.).

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2021 in npj Regenerative Medicine
Verified
Journal Article
Open access
PDF file
AGArmin Garmany
Armin Garmany
SYSatsuki Yamada
Satsuki Yamada
ATAndre Terzic
Andre Terzic
Life expectancy has increased by three decades since the mid-twentieth century. Parallel healthspan expansion has however not followed, largely impeded by the pandemic of chronic diseases afflicting a growing older population. The lag in quality of life is a recognized challenge that calls for prioritization of disease-free longevity. Contemporary communal, clinical and research trends aspiring to extend the health horizon are here outlined in the context of an evolving epidemiology. A shared action integrating public and societal endeavors with emerging interventions that target age-related multimorbidity and frailty is needed. A multidimensional buildout of a curative perspective, boosted by modern anti-senescent and regenerative technology with augmented decision making, would require dedicated resources and cost-effective validation to responsibly bridge the healthspan-lifespan gap for a future of equitable global wellbeing.

11 December 2024 in Regenerative Medicine
Verified
Journal Article
Open access
AGArmin Garmany
Armin Garmany
ATAndre Terzic
Andre Terzic
The expanding regenerative medicine toolkit is reaching a record number of lives. There is a pressing need to enhance the precision, efficiency, and effectiveness of regenerative approaches and achieve reliable outcomes. While regenerative medicine has relied on an empiric paradigm, availability of big data along with advances in informatics and artificial intelligence offer the opportunity to inform the next generation of regenerative sciences along the discovery, translation, and application pathway. Artificial intelligence can streamline discovery and development of optimized biotherapeutics by aiding in the interpretation of readouts associated with optimal repair outcomes. In advanced biomanufacturing, artificial intelligence holds potential in ensuring quality control and assuring scalability through automated monitoring of process-critical variables mandatory for product consistency. In practice application, artificial intelligence can guide clinical trial design, patient selection, delivery strategies, and outcome assessment. As artificial intelligence transforms the regenerative horizon, caution is necessary to reduce bias, ensure generalizability, and mitigate ethical concerns with the goal of equitable access for patients and populations.

28 May 2021 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
DAD. Kent Arrell
D. Kent Arrell
RCRuben J. Crespo-Diaz
Ruben J. Crespo-Diaz
SYSatsuki Yamada
Satsuki Yamada
RJRyounghoon Jeon
Ryounghoon Jeon
AGArmin Garmany
Armin Garmany
ATAndre Terzic
Andre Terzic
Stem cell paracrine activity is implicated in cardiac repair. Linkage between secretome functionality and therapeutic outcome was here interrogated by systems analytics of biobanked human cardiopoietic cells, a regenerative biologic in advanced clinical trials. Protein chip array identified 155 proteins differentially secreted by cardiopoietic cells with clinical benefit, expanded into a 520 node network, collectively revealing inherent vasculogenic properties along with cardiac and smooth muscle differentiation and development. Next generation RNA sequencing, refined by pathway analysis, pinpointed miR-146 dependent regulation upstream of the decoded secretome. Intracellular and extracellular integration unmasked commonality across cardio-vasculogenic processes. Mirroring the secretome pattern, infarcted hearts benefiting from cardiopoietic cell therapy restored the disease proteome engaging cardiovascular system functions. The cardiopoietic cell secretome thus confers a therapeutic molecular imprint on recipient hearts, with response informed by predictive systems profiling.

1 September 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
AGArmin Garmany
Armin Garmany
ATAndre Terzic
Andre Terzic
Background Longevity gains have not been matched by equivalent advances in healthy longevity, giving rise to the healthspan-lifespan gap. This study maps, by world region, the healthspan-lifespan gap; identifies gap-associated demographic, economic, and health indicators; and deciphers disease burden patterns contributing to gap profiles. Methods World Health Organization (WHO) Global Health Observatory, United Nations World Population Prospects and Global Health Expenditure Database were interrogated. The healthspan-lifespan gap was quantified from estimates of life expectancy and health-adjusted life expectancy. Regression analysis evaluated healthspan-lifespan gap correlates with a spatial error model used to adjust for confounders arising from geographic proximity. Dimensionality reduction by principal component analysis and clustering by machine learning discriminated disease burden patterns linked to healthspan-lifespan gap identity. Supervised machine learning enabled validation of disease burden pattern distinctness. Results Charted for six WHO-designated regions, comprising 183 member states, the healthspan-lifespan gap differs in size across regions. Life expectancy, gross domestic product, and noncommunicable disease burden most consistently correlate with the healthspan-lifespan gap. Unsupervised machine learning identifies three clusters delineating global morbidity patterns. Cluster-informed stratification discerns inter- and intra-regional gap heterogeneity. Africa, although exhibiting the narrowest healthspan-lifespan gap, is overrepresented in countries with larger than predicted healthspan-lifespan gaps and shows the greatest gap expansion and disease burden pattern restructuring. In contrast, Europe is overrepresented in countries with healthspan-lifespan gaps smaller than anticipated. Projections into 2100 forecast continuous widening of the healthspan-lifespan gap across regions. Conclusions The healthspan-lifespan gap is universal yet differs in magnitude and disease contribution among world regions. Gap identities imposed by distinct disease burden patterns caution against global generalization, necessitating region-informed solutions to maximize equitable healthy longevity.

25 June 2021 in Biomarkers in Medicine
Verified
Journal Article
Open access
SYSatsuki Yamada
Satsuki Yamada
RJRyounghoon Jeon
Ryounghoon Jeon
AGArmin Garmany
Armin Garmany
ABAtta Behfar
Atta Behfar
ATAndre Terzic
Andre Terzic
Risk of outcome variability challenges therapeutic innovation. Selection of the most suitable candidates is predicated on reliable response indicators. Especially for emergent regenerative biothera...

8 December 2018 in Chemosphere
Verified
Journal Article
Closed access
ASAmanda Smythers
Amanda Smythers
AGArmin Garmany
Armin Garmany
NPNicole L. Perry
Nicole L. Perry
EHEthan L. Higginbotham
Ethan L. Higginbotham
PAP. Ethan Adkins
P. Ethan Adkins
DKDerrick R.J. Kolling
Derrick R.J. Kolling